Phase I dose-escalation trial investigating the safety and tolerability of EP0906 plus estramustine in patients with advanced cancer.

被引：0
|
作者：
Wojtowicz, M
Rothermel, JD
Anderson, J
Todd, M
Rubin, EH
Dipaola, RS
机构：
[1] Canc Inst New Jersey, New Brunswick, NJ USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4623
引用
收藏
页码：412S / 412S
页数：1
相关论文
共 50 条
  • [1] Phase Ib/Il dose-escalation trial evaluating the safety and tolerability of EP0906 plus capecitabine in patients with advanced cancer.
    Dumez, H
    Van Oosterom, AT
    Rothermel, JD
    Mull, R
    Calvert, AH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 150S - 150S
  • [2] Phase I dose-escalation trial investigating the safety and tolerability of EPO906 plus gemcitabine in patients with advanced cancer
    Rinehart, JJ
    Rothermel, JD
    Anderson, J
    Lorusso, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 219S - 219S
  • [3] A phase I/II dose-escalation trial of EP0906 every 3 weeks in patients with relapsed/refractory ovarian, primary fallopian, or primary peritoneal cancer.
    Smit, WM
    Honkoop, AH
    Spanik, S
    Wagnerova, M
    Huinink, WWTB
    Oza, AM
    Kaye, SB
    Mull, R
    Pereno, R
    Sklenar, I
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 474S - 474S
  • [4] A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer
    I M E Desar
    J N H Timmer-Bonte
    D M Burger
    W T A van der Graaf
    C M L van Herpen
    British Journal of Cancer, 2010, 103 : 1637 - 1643
  • [5] A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer
    Desar, I. M. E.
    Timmer-Bonte, J. N. H.
    Burger, D. M.
    van der Graaf, W. T. A.
    van Herpen, C. M. L.
    BRITISH JOURNAL OF CANCER, 2010, 103 (11) : 1637 - 1643
  • [6] A phase I dose-escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer.
    Leong, S.
    Camidge, R.
    Eckhardt, G.
    Basche, M.
    Musib, L.
    Darstein, C.
    Thornton, D.
    Britten, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 91S - 91S
  • [7] Phase I dose-escalation and pharmacokinetic study of antrubicin in patients with recurrent advanced lung cancer.
    Okamoto, I
    Hamada, A
    Matsunaga, Y
    Sasaki, JI
    Fujii, S
    Uramoto, H
    Yamagata, H
    Mori, I
    Kishi, H
    Semba, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 151S - 151S
  • [8] A Phase IIa trial of weekly EP0906 in patients with hormone-refractory prostate cancer (HPRC).
    Hussain, A
    Dipaola, RS
    Baron, AD
    Higano, CS
    Tchekmediyan, NS
    Miller, JA
    Rothermel, JD
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 397S - 397S
  • [9] Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial
    Georgoff, Patrick E.
    Nikolian, Vahagn C.
    Bonham, Tess
    Pai, Manjunath P.
    Tafatia, Celia
    Halaweish, Ihab
    To, Kathleen
    Watcharotone, Kuanwong
    Parameswaran, Aishwarya
    Luo, Ruijuan
    Sun, Duxin
    Alam, Hasan B.
    CLINICAL PHARMACOKINETICS, 2018, 57 (02) : 209 - 219
  • [10] Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial
    Patrick E. Georgoff
    Vahagn C. Nikolian
    Tess Bonham
    Manjunath P. Pai
    Celia Tafatia
    Ihab Halaweish
    Kathleen To
    Kuanwong Watcharotone
    Aishwarya Parameswaran
    Ruijuan Luo
    Duxin Sun
    Hasan B. Alam
    Clinical Pharmacokinetics, 2018, 57 : 209 - 219
12345